187 related articles for article (PubMed ID: 14642684)
21. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
22. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Diep QN; El Mabrouk M; Cohn JS; Endemann D; Amiri F; Virdis A; Neves MF; Schiffrin EL
Circulation; 2002 May; 105(19):2296-302. PubMed ID: 12010913
[TBL] [Abstract][Full Text] [Related]
23. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
Wang CH; Ciliberti N; Li SH; Szmitko PE; Weisel RD; Fedak PW; Al-Omran M; Cherng WJ; Li RK; Stanford WL; Verma S
Circulation; 2004 Mar; 109(11):1392-400. PubMed ID: 14993120
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
[TBL] [Abstract][Full Text] [Related]
28. Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.
Jiang G; Dallas-Yang Q; Biswas S; Li Z; Zhang BB
Biochem J; 2004 Jan; 377(Pt 2):339-46. PubMed ID: 14556646
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats.
Rinaldi B; Pieri L; Donniacuo M; Cappetta D; Capuano A; Domenici L; Carnuccio R; Romagnoli P; Filippelli A; Rossi F
Shock; 2009 Dec; 32(6):638-44. PubMed ID: 19333142
[TBL] [Abstract][Full Text] [Related]
31. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Doležalová R; Haluzík MM; Bošanská L; Lacinová Z; Kasalová Z; Stulc T; Haluzík M
Physiol Res; 2007; 56(6):741-748. PubMed ID: 17087601
[TBL] [Abstract][Full Text] [Related]
32. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
33. Evidence for a potent antiinflammatory effect of rosiglitazone.
Mohanty P; Aljada A; Ghanim H; Hofmeyer D; Tripathy D; Syed T; Al-Haddad W; Dhindsa S; Dandona P
J Clin Endocrinol Metab; 2004 Jun; 89(6):2728-35. PubMed ID: 15181049
[TBL] [Abstract][Full Text] [Related]
34. A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.
Bertrand OF; Poirier P; Rodés-Cabau J; Rinfret S; Title L; Dzavik V; Natarajan M; Angel J; Batalla N; Alméras N; Costerousse O; De Larochellière R; Roy L; Després JP;
Can J Cardiol; 2009 Sep; 25(9):509-15. PubMed ID: 19746240
[TBL] [Abstract][Full Text] [Related]
35. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
[TBL] [Abstract][Full Text] [Related]
36. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.
Tao L; Liu HR; Gao E; Teng ZP; Lopez BL; Christopher TA; Ma XL; Batinic-Haberle I; Willette RN; Ohlstein EH; Yue TL
Circulation; 2003 Dec; 108(22):2805-11. PubMed ID: 14610009
[TBL] [Abstract][Full Text] [Related]
37. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
38. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation.
Plutzky J
J Am Coll Cardiol; 2003 Nov; 42(10):1764-6. PubMed ID: 14642685
[No Abstract] [Full Text] [Related]
40. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
Ryan MJ; Didion SP; Mathur S; Faraci FM; Sigmund CD
Hypertension; 2004 Mar; 43(3):661-6. PubMed ID: 14744930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
